Table 1:
Baseline characteristics of patients
| Characteristic | Total (N = 10) |
|---|---|
| Age – Median (range) | 28 (23–36) |
| Female sex* – no. (%) | 6 (60%) |
| Race – no. (%) | |
| White | 9 (90%) |
| African American | 1 (10%) |
| Ethnicity – no. (%) | |
| Hispanic or Latino | 3 (30%) |
| Not Hispanic or Latino | 7 (70%) |
| Atopic comorbidities – no. (%) | |
| Allergy to other foods | 7 (70%) |
| Tree nuts | 6 (60%) |
| Soy | 2 (20%) |
| Other legumes | 1 (10%) |
| Asthma | 7 (70%) |
| Rhinitis | 9 (90%) |
| Atopic dermatitis | 2 (20%) |
| Approximate time since last accidental exposure to peanut in months – Median (range) | 32.5 (9–72) |
| History of epinephrine autoinjector use for peanut exposure – no. (%) | |
| Yes | 6 (60%) |
| No | 2 (20%) |
| Unsure | 2 (20%) |
| History of emergency room visit for peanut exposure – no. (%) | 8 (80%) |
| History of hospitalization for peanut exposure – no. (%) | 2 (20%) |
| Baseline maximum tolerated peanut dose during oral food challenge in mg – Median (range) | 29 (1–444) |
| Peanut extract skin puncture test wheal area in mm2 – Median (range) | 125.7 (27.5–480.7) |
| Serum specific IgEs in kUA/L – Median (range)** | |
| Peanut | 4.9 (0–335.0) |
| Ara h 1 | 0.13 (0–123.0) |
| Ara h 2 | 1.9 (0–131.0) |
| Ara h 3 | <0.1 (0–33.2) |
| Ara h 6 | 2.3 (0–82.7) |
| Ara h 8 | 0.18 (0–5.1) |
| Ara h 9 | <0.1 (0–3.4) |
| Total IgE in kU/L – Median (range) | 117.0 (18.6–2939) |
*
One patient is transgender (assigned female sex at birth, currently identifying as male)
**
Limit of detection was 0.1 kUA/L